

Shuo-Feng Yuan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1435166/publications.pdf>

Version: 2024-02-01

85
papers

18,568
citations

101543

36
h-index

56724

83
g-index

91
all docs

91
docs citations

91
times ranked

33024
citing authors

#	ARTICLE	IF	CITATIONS
1	A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. <i>Lancet, The</i> , 2020, 395, 514-523.	13.7	7,120
2	Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. <i>Emerging Microbes and Infections</i> , 2020, 9, 221-236.	6.5	2,389
3	Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility. <i>Clinical Infectious Diseases</i> , 2020, 71, 2428-2446.	5.8	839
4	Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. <i>Lancet Microbe, The</i> , 2020, 1, e14-e23.	7.3	683
5	Zoonotic origins of human coronaviruses. <i>International Journal of Biological Sciences</i> , 2020, 16, 1686-1697.	6.4	680
6	Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. <i>Nature</i> , 2020, 586, 113-119.	27.8	672
7	Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. <i>Clinical Infectious Diseases</i> , 2021, 73, e2946-e2951.	5.8	647
8	Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19. <i>Clinical Infectious Diseases</i> , 2020, 71, 1400-1409.	5.8	561
9	Surgical Mask Partition Reduces the Risk of Noncontact Transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2020, 71, 2139-2149.	5.8	501
10	Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. <i>Nature</i> , 2022, 603, 693-699.	27.8	460
11	Severe acute respiratory syndrome Coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. <i>FASEB Journal</i> , 2019, 33, 8865-8877.	0.5	434
12	Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication. <i>Viruses</i> , 2019, 11, 73.	3.3	228
13	Differentiated human airway organoids to assess infectivity of emerging influenza virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 6822-6827.	7.1	215
14	SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. <i>Nature Communications</i> , 2019, 10, 120.	12.8	192
15	Attenuated Interferon and Proinflammatory Response in SARS-CoV-2-Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation. <i>Journal of Infectious Diseases</i> , 2020, 222, 734-745.	4.0	165
16	Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells. <i>Journal of Biological Chemistry</i> , 2018, 293, 11709-11726.	3.4	153
17	Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. <i>Nature</i> , 2021, 593, 418-423.	27.8	151
18	Metallo drug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. <i>Nature Microbiology</i> , 2020, 5, 1439-1448.	13.3	140

#	ARTICLE	IF	CITATIONS
19	Emerging SARS-CoV-2 variants expand species tropism to murines. <i>EBioMedicine</i> , 2021, 73, 103643.	6.1	127
20	Oral SARS-CoV-2 Inoculation Establishes Subclinical Respiratory Infection with Virus Shedding in Golden Syrian Hamsters. <i>Cell Reports Medicine</i> , 2020, 1, 100121.	6.5	121
21	Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. <i>Science</i> , 2022, 377, 428-433.	12.6	113
22	Host and viral determinants for efficient SARS-CoV-2 infection of the human lung. <i>Nature Communications</i> , 2021, 12, 134.	12.8	112
23	Severe Acute Respiratory Syndrome Coronavirus 2 Infects and Damages the Mature and Immature Olfactory Sensory Neurons of Hamsters. <i>Clinical Infectious Diseases</i> , 2021, 73, e503-e512.	5.8	106
24	Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor. <i>Antiviral Research</i> , 2017, 141, 29-37.	4.1	102
25	Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in <i>in vitro</i> and <i>in vivo</i> . <i>Antiviral Research</i> , 2017, 145, 33-43.	4.1	99
26	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 551-563.e5.	11.0	87
27	Coinfection by Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza A(H1N1)pdm09 Virus Enhances the Severity of Pneumonia in Golden Syrian Hamsters. <i>Clinical Infectious Diseases</i> , 2021, 72, e978-e992.	5.8	84
28	Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza. <i>Nature Communications</i> , 2018, 9, 2358.	12.8	63
29	Competing endogenous RNA network profiling reveals novel host dependency factors required for MERS-CoV propagation. <i>Emerging Microbes and Infections</i> , 2020, 9, 733-746.	6.5	58
30	Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. <i>Pharmacological Research</i> , 2020, 159, 104960.	7.1	56
31	Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). <i>Viruses</i> , 2020, 12, 628.	3.3	55
32	Serum Antibody Profile of a Patient With Coronavirus Disease 2019 Reinfection. <i>Clinical Infectious Diseases</i> , 2021, 72, e659-e662.	5.8	50
33	Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. <i>Emerging Microbes and Infections</i> , 2021, 10, 291-304.	6.5	48
34	Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity. <i>Science Advances</i> , 2021, 7, .	10.3	48
35	Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase. <i>Antiviral Research</i> , 2016, 125, 34-42.	4.1	41
36	SARS-CoV-2 Induces a More Robust Innate Immune Response and Replicates Less Efficiently Than SARS-CoV in the Human Intestines: An <i>Ex vivo</i> Study With Implications on Pathogenesis of COVID-19. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 771-781.	4.5	41

#	ARTICLE	IF	CITATIONS
37	Viruses harness YxxÅ ⁿ motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target. <i>Science Advances</i> , 2020, 6, eaba7910.	10.3	40
38	Cross-Protection of Influenza A Virus Infection by a DNA Aptamer Targeting the PA Endonuclease Domain. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4082-4093.	3.2	38
39	A novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase. <i>Scientific Reports</i> , 2016, 6, 22880.	3.3	37
40	The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy. <i>Antiviral Research</i> , 2018, 160, 38-47.	4.1	35
41	PB2 substitutions V598T/I increase the virulence of H7N9 influenza A virus in mammals. <i>Virology</i> , 2017, 501, 92-101.	2.4	34
42	Antibody-Dependent Cell-Mediated Cytotoxicity Epitopes on the Hemagglutinin Head Region of Pandemic H1N1 Influenza Virus Play Detrimental Roles in H1N1-Infected Mice. <i>Frontiers in Immunology</i> , 2017, 8, 317.	4.8	32
43	COVID-19 in Joint Ageing and Osteoarthritis: Current Status and Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 720.	4.1	32
44	An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. <i>Science Translational Medicine</i> , 2022, 14, eabn6859.	12.4	31
45	A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2489-2497.	3.0	30
46	Middle East Respiratory Syndrome Coronavirus ORF8b Accessory Protein Suppresses Type I IFN Expression by Impeding HSP70-Dependent Activation of IRF3 Kinase IKKÎµ. <i>Journal of Immunology</i> , 2020, 205, 1564-1579.	0.8	30
47	SARS-CoV-2 exploits host DGAT and ADRP for efficient replication. <i>Cell Discovery</i> , 2021, 7, 100.	6.7	29
48	Lipidomic Profiling Reveals Significant Perturbations of Intracellular Lipid Homeostasis in Enterovirus-Infected Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5952.	4.1	27
49	Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. , 2022, 19, 588-601.		27
50	Amino acid substitutions V63I or A37S/I61T/V63I/V100A in the PA N-terminal domain increase the virulence of H7N7 influenza A virus. <i>Scientific Reports</i> , 2016, 6, 37800.	3.3	25
51	Targeting papain-like protease for broad-spectrum coronavirus inhibition. <i>Protein and Cell</i> , 2022, 13, 940-953.	11.0	23
52	SARS-CoV-2 infection induces inflammatory bone loss in golden Syrian hamsters. <i>Nature Communications</i> , 2022, 13, 2539.	12.8	22
53	Screening of an FDA-Approved Drug Library with a Two-Tier System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia Syndrome Virus. <i>Viruses</i> , 2019, 11, 385.	3.3	20
54	Identification and characterization of <sc>GLDC</sc> as host susceptibility gene to severe influenza. <i>EMBO Molecular Medicine</i> , 2019, 11, .	6.9	20

#	ARTICLE	IF	CITATIONS
55	Probable Animal-to-Human Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Variant AY.127 Causing a Pet Shop-Related Coronavirus Disease 2019 (COVID-19) Outbreak in Hong Kong. <i>Clinical Infectious Diseases</i> , 2022, 75, e76-e81.	5.8	20
56	Inhibitors of Influenza A Virus Polymerase. <i>ACS Infectious Diseases</i> , 2018, 4, 218-223.	3.8	19
57	Targeting SUMO Modification of the Non-Structural Protein 5 of Zika Virus as a Host-Targeting Antiviral Strategy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 392.	4.1	19
58	Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy. <i>Chemical Science</i> , 2022, 13, 2238-2248.	7.4	19
59	Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface. <i>Antiviral Research</i> , 2017, 137, 58-66.	4.1	18
60	Low Environmental Temperature Exacerbates Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Golden Syrian Hamsters. <i>Clinical Infectious Diseases</i> , 2022, 75, e1101-e1111.	5.8	17
61	Development of Three-Dimensional Human Intestinal Organoids as a Physiologically Relevant Model for Characterizing the Viral Replication Kinetics and Antiviral Susceptibility of Enteroviruses. <i>Biomedicines</i> , 2021, 9, 88.	3.2	15
62	Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant. <i>Viruses</i> , 2022, 14, 501.	3.3	15
63	Metal-based strategies for the fight against COVID-19. <i>Chemical Communications</i> , 2022, 58, 7466-7482.	4.1	14
64	Large-scale sequence analysis reveals novel human-adaptive markers in PB2 segment of seasonal influenza A viruses. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-12.	6.5	13
65	A new class of Î±-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities. <i>European Journal of Medicinal Chemistry</i> , 2021, 215, 113267.	5.5	13
66	Novel residues in the PA protein of avian influenza H7N7 virus affect virulence in mammalian hosts. <i>Virology</i> , 2016, 498, 1-8.	2.4	12
67	STAT2-dependent restriction of Zika virus by human macrophages but not dendritic cells. <i>Emerging Microbes and Infections</i> , 2021, 10, 1024-1037.	6.5	12
68	In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor. <i>International Journal of Biological Sciences</i> , 2021, 17, 1555-1564.	6.4	12
69	Inhaled Dry Powder Formulation of Tamibarotene, a Broad-Spectrum Antiviral against Respiratory Viruses Including SARS-CoV-2 and Influenza Virus. <i>Advanced Therapeutics</i> , 2021, 4, 2100059.	3.2	12
70	A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters. <i>Emerging Microbes and Infections</i> , 2021, 10, 874-884.	6.5	11
71	Metabolic Profiling Reveals Significant Perturbations of Intracellular Glucose Homeostasis in Enterovirus-Infected Cells. <i>Metabolites</i> , 2020, 10, 302.	2.9	9
72	Targeting the Inositol-Requiring Enzyme-1 Pathway Efficiently Reverts Zika Virus-Induced Neurogenesis and Spermatogenesis Marker Perturbations. <i>ACS Infectious Diseases</i> , 2020, 6, 1745-1758.	3.8	9

#	ARTICLE	IF	CITATIONS
73	Peptide-Mediated Interference of PB2-eIF4G1 Interaction Inhibits Influenza A Virusesâ€™™ Replication in Vitro and in Vivo. <i>ACS Infectious Diseases</i> , 2016, 2, 471-477.	3.8	8
74	hnRNP C modulates MERS-CoV and SARS-CoV-2 replication by governing the expression of a subset of circRNAs and cognitive mRNAs. <i>Emerging Microbes and Infections</i> , 2022, 11, 519-531.	6.5	8
75	Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration. <i>International Journal of Pharmaceutics</i> , 2022, 619, 121704.	5.2	6
76	PA N substitutions A37S, A37S/I61T and A37S/V63I attenuate the replication of H7N7 influenza A virus by impairing the polymerase and endonuclease activities. <i>Journal of General Virology</i> , 2017, 98, 364-373.	2.9	5
77	SPINK6 inhibits human airway serine proteases and restricts influenza virus activation. <i>EMBO Molecular Medicine</i> , 2022, 14, e14485.	6.9	5
78	Multiplex metal-detection based assay (MMDA) for COVID-19 diagnosis and identification of disease severity biomarkers. <i>Chemical Science</i> , 2022, 13, 3216-3226.	7.4	5
79	Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo. <i>Cell Research</i> , 2022, 32, 589-592.	12.0	5
80	TRAF3 Positively Regulates Host Innate Immune Resistance to Influenza A Virus Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 839625.	3.9	5
81	Establishment of a lethal aged mouse model of human respiratory syncytial virus infection. <i>Antiviral Research</i> , 2019, 161, 125-133.	4.1	4
82	Prediction and characterization of influenza virus polymerase inhibitors through blind docking and ligand based virtual screening. <i>Journal of Molecular Liquids</i> , 2021, 321, 114784.	4.9	3
83	Severe fever with thrombocytopenia syndrome virus (SFTSV)-host interactome screen identifies viral nucleoprotein-associated host factors as potential antiviral targets. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 5568-5577.	4.1	3
84	1899. The Cellular Kinase Inhibitor OSU-03012 Inhibits Enterovirus 71 In Vitro. <i>Open Forum Infectious Diseases</i> , 2018, 5, S545-S545.	0.9	0
85	In Silico Structure-Based Design of Antiviral Peptides Targeting the Severe Fever with Thrombocytopenia Syndrome Virus Glycoprotein Gn. <i>Viruses</i> , 2021, 13, 2047.	3.3	0